Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Javier Cortes

Showing results (91-100 of 231) with videos related to

Pageof 24
Sort By:
CA: a Cancer Journal for Clinicians|November 12, 2021
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologiesPaolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
BMC Public Health|July 20, 2023
Mapping the risk of respiratory infections using suburban district areas in a large city in ColombiaJavier Cortes-Ramirez, Michelle Gatton, Juan D Wilches-Vega, et al.
Journal of Orofacial Pain|April 30, 2011
Oral pain and eating problems in Spanish adults and elderly in the Spanish National Survey performed in 2005Javier Montero, Manuel Bravo, Maria-Purificacion Vicente, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancerXavier Pivot, Mark Pegram, Javier Cortes, et al.
Breast Cancer Research and Treatment|November 15, 2015
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialJavier Cortes, Stacie Hudgens, Chris Twelves, et al.
NPJ Breast Cancer|February 19, 2022
Immunotherapy for early triple negative breast cancer: research agenda for the next decadePaolo Tarantino, Chiara Corti, Peter Schmid, et al.
The Oncologist|April 1, 2014
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancerHyman Muss, Javier Cortes, Linda T Vahdat, et al.
Breast (Edinburgh, Scotland)|November 10, 2012
Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosisDavis Torrejón, Mafalda Oliveira, Javier Cortes, et al.
Clinical Breast Cancer|April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST AnalysisJavier Cortes, José Pérez-García, Scott Whiting, et al.
Targeted Oncology|October 14, 2025
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast CancerRichard S Finn, Hope S Rugo, Javier Cortes, et al.
Pageof 24

Showing results (91-100 of 231) with videos related to

Sort By:
Pageof 24
CA: a Cancer Journal for Clinicians|November 12, 2021
Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologiesPaolo Tarantino, Roberto Carmagnani Pestana, Chiara Corti, et al.
BMC Public Health|July 20, 2023
Mapping the risk of respiratory infections using suburban district areas in a large city in ColombiaJavier Cortes-Ramirez, Michelle Gatton, Juan D Wilches-Vega, et al.
Journal of Orofacial Pain|April 30, 2011
Oral pain and eating problems in Spanish adults and elderly in the Spanish National Survey performed in 2005Javier Montero, Manuel Bravo, Maria-Purificacion Vicente, et al.
European Journal of Cancer (Oxford, England : 1990)|August 25, 2019
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancerXavier Pivot, Mark Pegram, Javier Cortes, et al.
Breast Cancer Research and Treatment|November 15, 2015
Health-related quality of life in patients with locally advanced or metastatic breast cancer treated with eribulin mesylate or capecitabine in an open-label randomized phase 3 trialJavier Cortes, Stacie Hudgens, Chris Twelves, et al.
NPJ Breast Cancer|February 19, 2022
Immunotherapy for early triple negative breast cancer: research agenda for the next decadePaolo Tarantino, Chiara Corti, Peter Schmid, et al.
The Oncologist|April 1, 2014
Eribulin monotherapy in patients aged 70 years and older with metastatic breast cancerHyman Muss, Javier Cortes, Linda T Vahdat, et al.
Breast (Edinburgh, Scotland)|November 10, 2012
Implication of breast cancer phenotype for patients with leptomeningeal carcinomatosisDavis Torrejón, Mafalda Oliveira, Javier Cortes, et al.
Clinical Breast Cancer|April 29, 2018
Quality-Adjusted Survival With nab-Paclitaxel Versus Standard Paclitaxel in Metastatic Breast Cancer: A Q-TWiST AnalysisJavier Cortes, José Pérez-García, Scott Whiting, et al.
Targeted Oncology|October 14, 2025
A Decade After Approval of the First CDK4/6 Inhibitor: A Look Back at Palbociclib's Journey from Discovery to Approval and What's Next in CDK Inhibition in Breast CancerRichard S Finn, Hope S Rugo, Javier Cortes, et al.
Pageof 24